Announcements

Serina Therapeutics, Inc. (AMEX: SER) is advancing SER-252 into the next cohort of its ongoing Phase 1b study in patients with advanced Parkinson’s disease.

Opaleye Management Inc. a 10% owner of Sol-Gel Technologies Ltd. (NASDAQ: SLGL), purchased 9,976 shares across five transactions between 4 September 2026 and 9 September 2026. The purchases carried SEC transaction code P.

Teleflex Inc (NYSE: TFX) appointed Sean M. Salmon to its board on September 8, 2026, adding medical-technologyLeadershiptied to a former Medtronic cardiovascularBusinesswith approximately $12.5 billion in fiscal 2025 revenue. Salmon also joined Teleflex’s Growth and Operating Committee.

NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) will consolidate every 20 ordinary shares into one under a 1-for-20 reverse split. The transaction will reduce issued and outstanding ordinary shares from 37,938,036 to 1,896,902, subject to any further adjustment arising from fractional-share treatment.

NovoCure Ltd (NASDAQ: NVCR) lost Timothy Scannell from its Board effective September 2, 2026, when his seat was vacated under the company’s Articles of Association. The retirement was not attributed to any disagreement with NovoCure or its management.

Novo Nordisk’s repurchase programme accumulated 17,275,000 B shares worth DKK 5,221,774,293, while totalBuybackssince 4 February reached 32,034,179 shares worth DKK 9,021,774,283. The purchases left 46,074,876 B shares in treasury, equal to 1.0% of share capital.Key HighlightsNovo Nordisk repurchased 32,034,179 B shares since 4 February …

Odyssey Therapeutics, Inc. (NASDAQ: ODTX) outlined a $433 million cash balance as of June 30 and said it expects the funds to support operations into H2 2028. The presentation also set out clinical milestones for its inflammatory and autoimmune disease programs.